List view / Grid view

News

Teva’s severe eosinophilic asthma drug Cinqaero wins EU approval

18 August 2016 | By Caroline Richards, Editor, European Pharmaceutical Review & Drug Target Review

Cinqaero is a humanised interleukin-5 antagonist monoclonal antibody (IgG4 kappa) for add-on therapy in adult patients with severe eosinophilic asthma inadequately controlled despite high-dose inhaled corticosteroids plus another medicinal product for maintenance treatment...

NICE says Novartis’ and Janssen’s cancer drugs are not cost effective

18 August 2016 | By The National Institute for Health and Care Excellence (NICE)

In new draft guidance, the National Institute for Health and Care Excellence (NICE) has advised that everolimus, for treating advanced breast cancer after endocrine therapy, and ibrutinib, for treating relapsed or refractory mantle cell lymphoma, two drugs on the Cancer Drugs Fund are not cost effective. 

Gene activity linked to breast cancer survival

18 August 2016 | By The Institute of Cancer Research, London

In a study of nearly 2000 patients, researchers found that women whose tumours had high F12 activity and low STC2 activity had a 32% chance of dying within 10 years, whereas those with low F12 activity and high STC2 activity had only a 10% chance of dying...

NICE recommends Pfizer’s lung cancer drug after price drop

18 August 2016 | By The National Institute for Health and Care Excellence (NICE)

When initially reviewed, the committee concluded that the drug was too expensive compared to the current standard of care. Pfizer submitted further evidence, including a new patient access scheme that provided the drug at a lower price alongside revised analyses, which the committee then concluded could now be considered value…

Evgen Pharma receives UK approval for breast cancer trial

17 August 2016 | By Evgen Pharma

The primary objectives of the STEM (SFX-01 in the Treatment and Evaluation of Metastatic Breast Cancer) trial are to use tumour imaging to evaluate safety and efficacy in patients starting to become resistant to mainstream hormone therapy...

Global dual-drug trial aims to advance HIV treatment

16 August 2016 | By ViiV Healthcare

ViiV Healthcare is undertaking two identical studies as part of a global phase III programme comparing a two-drug regimen of dolutegravir plus lamivudine, with a three-drug regimen of dolutegravir (Tivicay), plus the fixed-dose tablet tenofovir/emtricitabine (Truvada), to support regulatory filings as a treatment for HIV, for adults who have had…

Biomarker breakthrough could improve Parkinson’s treatment

16 August 2016 | By University of Florida

Scientists have found that using magnetic resonance imaging reveals areas where Parkinson’s disease causes progressive decline in brain activity, a biomarker discovery which will help to evaluate new experimental treatments to slow or stop the disease’s progression...

NICE recommends thousands to receive £2-a-day anti-clotting drug

15 August 2016 | By National Institute for Health and Care Excellence (NICE)

A higher dose of ticagrelor is already recommended for 12 months after a heart attack. Now new draft guidance is recommending it is continued in these people at a lower dose for a further three years to reduce their risk of a further heart attack or stroke...

Sanofi sends half a million dengue vaccines to high risk Brazilians

15 August 2016 | By Sanofi

Results of the study affirm the vaccine's consistent efficacy in reducing dengue in two-thirds of the study participants, aged 9 and older. It also documents the ability of the vaccine to prevent 8 out of 10 hospitalisations and up to 93% of severe dengue cases in this age group during…

Depression symptoms in remission after correcting metabolic deficiencies

12 August 2016 | By Niamh Louise Marriott, Digital Content Producer

Searching for answers through a series of biochemical tests, the scientists discovered that the patient had a cerebrospinal fluid deficiency in biopterin, a protein involved in the synthesis of several brain signalling chemicals called neurotransmitters. After receiving an analogue of biopterin to correct the deficiency, the patient's depression symptoms largely…

Acacia Pharma’s antiemetic drug prevents post-op nausea and vomiting

12 August 2016 | By Acacia Pharma

Acacia Pharma’s phase 3 trial, comprised of 568 patients, compared two doses of Baremsis (amisulpride injection, formerly APD421), a dopamine D2/D3 antagonist antiemetic, against placebo in patients with established nausea and/or vomiting after surgery (PONV), who had not previously received any prophylactic antiemetics...